Catalyst Biosciences Receives Orphan Designation from the European Commission for Marzeptacog Alfa (Activated) for the treatment of haemophilia B April 1, 2019https://apnews.com/Globe%2520Newswire/c4cb1fde71d3ddf1d8a53baa025e5dbe Catalyst Biosciences Receives Orphan Designation from the European Commission for Marzeptacog Alfa (Activated)
